 | |
| Clinical data | |
|---|---|
| Trade names | Comfyde (proposed) |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C9H10ClNO3 |
| Molar mass | 215.63 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Carisbamate (YKP 509, proposed trade nameComfyde) is an experimentalanticonvulsant drug that was under development byJohnson & Johnson Pharmaceutical Research and Development but never marketed.
A phase II clinical trial in the treatment of partial seizures demonstrated that the compound has efficacy in the treatment of partial seizures and a good safety profile. Since late 2006, the compound has been undergoing a large multicenter phase III clinical trial for the treatment of partial seizures. Itsmechanism of action is unknown.[1][2]
A double-blind, placebo-controlled trial of carisbamate in 323 patients with migraine determined that carisbamate was well tolerated at doses up to 600 mg/day, but it failed to demonstrate that the drug was sufficiently more effective than placebo in migraine prophylaxis.[3]
In 1998, the compound was in-licensed from SK Corp. (currently Life Science Business Division ofSK Holdings), a South Korean company. On October 24, 2008,Johnson & Johnson announced that it had submitted aNew Drug Application to theU.S. Food and Drug Administration (FDA) for carisbamate.[4] Johnson & Johnson received provisional approval by the FDA to market carisbamate under the brand name of Comfyde. However, on August 21, 2009, Johnson & Johnson reported that the FDA had failed to give marketing approval.
